Compare Enveric Biosciences Inc (ENVB) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.57 (market cap $1.45B). The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is far larger — about 213.2× Enveric Biosciences Inc's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days on average.
| ENVB | QQQE | |
|---|---|---|
Market Cap | $6.80M | $1.45B |
Volume | 64,867 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $124.69 |
52-Week Low | $1.27 | $96.06 |
Typical Hold Time | 14 Days | 47 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.58, down 0.25% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 companies, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers tactical advantages over QQQ for the next twelve months due to its equal-weight methodology.
The outlook for QQQE appears favorable as equal weighting provides diversification benefits amid potential tech sector volatility. Key risks include NASDAQ concentration and market sensitivity, but the ETF's structure offers balanced exposure to large-cap growth stocks. Technical support levels at $120-121 provide near-term downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
